1. A.07 Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: a single-attack phase 3 study, ACHIEVE I. (5th June 2019) Authors: Dodick, DW; Lipton, RB; Ailani, J; Lu, K; Lakkis, H; Finnegan, M; Trugman, JM; Szegedi, A; Davidovic, G Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A.07 Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: a single-attack phase 3 study, ACHIEVE I. (June 2019) Authors: Dodick, DW; Lipton, RB; Ailani, J; Lu, K; Lakkis, H; Finnegan, M; Trugman, JM; Szegedi, A; Davidovic, G Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P.010 Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: a single-attack phase 3 study, ACHIEVE II. (5th June 2019) Authors: Lipton, RB; Dodick, DW; Ailani, J; Lu, K; Lakkis, H; Finnegan, M; Szegedi, A; Trugman, JM; Davidovic, G Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P.010 Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: a single-attack phase 3 study, ACHIEVE II. (June 2019) Authors: Lipton, RB; Dodick, DW; Ailani, J; Lu, K; Lakkis, H; Finnegan, M; Szegedi, A; Trugman, JM; Davidovic, G Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P.011 OnabotulinumtoxinA, quality of life, health resource utilization, and work productivity in chronic migraine: interim results from PREDICT. (5th June 2019) Authors: Boudreau, G; Becker, WJ; Graboski, C; Ong-Lam, M; Finkelstein, I; Christie, S; Bhogal, M; Davidovic, G Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P.011 OnabotulinumtoxinA, quality of life, health resource utilization, and work productivity in chronic migraine: interim results from PREDICT. (June 2019) Authors: Boudreau, G; Becker, WJ; Graboski, C; Ong-Lam, M; Finkelstein, I; Christie, S; Bhogal, M; Davidovic, G Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P.014 OnabotulinumtoxinA-treated cervical dystonia patients report improvements in health-related quality of life in a prospective, observational study: POSTURe. (5th June 2019) Authors: Petitclerc, M; Cloutier, M; Bhogal, M; Davidovic, G Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P.014 OnabotulinumtoxinA-treated cervical dystonia patients report improvements in health-related quality of life in a prospective, observational study: POSTURe. (June 2019) Authors: Petitclerc, M; Cloutier, M; Bhogal, M; Davidovic, G Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P.021 Evaluation of PREEMPT fixed-dose, fixed-site and follow the pain treatment paradigms in the PREDICT Study. (June 2022) Authors: Graboski, C; Ong-Lam, M; Becker, W; Boudreau, G; Davidovic, G; Ma, J; Sommer, K; Finkelstein, I Journal: Canadian journal of neurological sciences Issue: Volume 49(2022)Supplement 1 Page Start: S13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P.029 Oral Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days. (November 2021) Authors: Lipton, RB; Pozo-Rosich, P; Blumenfeld, AM; Dodick, DW; McAllister, P; Li, Y; Lu, K; Dabruzzo, B; Davidovic, G; Miceli, R; Severt, L; Finnegan, M; Trugman, JM Journal: Canadian journal of neurological sciences Issue: Volume 48(2021)Supplement S3 Page Start: S28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗